Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bioengineered foods

This article was originally published in The Tan Sheet

Executive Summary

FDA seeking comments by March 19 on whether statements such as "GM free," "biotech free" and "no genetically engineered materials" can be made on food packaging without being false and misleading. A draft guidance on voluntary labeling for bioengineered foods was published in the Jan. 18 Federal Register. Despite considerable comment to the contrary, FDA says evidence does not support mandatory statements identifying the inclusion of bioengineered foods or ingredients on labeling. Agency also published proposed rule requiring data regarding plant-derived bioengineered foods be submitted to FDA at least 120 days prior to commercial distribution. CFSAN says the guidance applies to all food labeling, which would encompass supplements and functional foods that contain ingredients such as bioengineered soybeans

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS092095

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel